Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Lerner

Showing results (181-190 of 183) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 183 results.
The Lancet. Oncology|November 10, 2016
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trialJoel W Neal, Suzanne E Dahlberg, Heather A Wakelee, et al.
Blood|May 31, 2024
Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCLMitchell R Smith, Opeyemi A Jegede, Peter Martin, et al.
JCO Oncology Practice|April 28, 2026
Engendering Reproductive Health Within Oncologic Survivorship Trial, ECOG-ACRIN E1Q11Ashlesha A Patel, Ju-Whei Lee, Howard A Zaren, et al.
Pageof 19

Showing results (181-190 of 183) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 183 results.
The Lancet. Oncology|November 10, 2016
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trialJoel W Neal, Suzanne E Dahlberg, Heather A Wakelee, et al.
Blood|May 31, 2024
Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCLMitchell R Smith, Opeyemi A Jegede, Peter Martin, et al.
JCO Oncology Practice|April 28, 2026
Engendering Reproductive Health Within Oncologic Survivorship Trial, ECOG-ACRIN E1Q11Ashlesha A Patel, Ju-Whei Lee, Howard A Zaren, et al.
Pageof 19